WHO temporarily pauses hydroxychloroquine study, citing safety concerns
The World Health Organization is temporarily halting a study on hydroxychloroquine and chloroquine as potential COVID-19 treatments due to safety concerns.
WHO Director-General Tedros Adhanom Ghebreyesus announced the decision on Monday, after a study published in The Lancet medical journal suggested COVID-19 patients treated with hydroxychloroquine and chloroquine were more likely to die, CNN reports. The drugs were being reviewed as part of the WHO's Solidarity Trial — a coronavirus research effort involving more than 400 hospitals in 35 countries.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Data Safety Monitoring Board will review data about the drugs to assess whether they should continue to be used in the trial, though other arms of the trial will carry on, per CNN.
Tedros noted the halt concerns hydroxychloroquine and chloroquine as they pertain to COVID-19. "I wish to reiterate that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria," he said.
